146 related articles for article (PubMed ID: 23873785)
21. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
22. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.
Amer-Salas N; González-Morcillo G; Rodríguez-Camacho JM; Cladera-Serra A
J Oncol Pharm Pract; 2021 Jan; 27(1):244-249. PubMed ID: 32517638
[TBL] [Abstract][Full Text] [Related]
23. Severe, reversible nelarabine-induced neuropathy and myelopathy.
Alberti P; Parma M; Pioltelli P; Pogliani EM; Terruzzi E; Stasia A; Doni E; Cecchetti C; Cavaletti G
J Peripher Nerv Syst; 2016 Sep; 21(3):154-6. PubMed ID: 27117493
[No Abstract] [Full Text] [Related]
24. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
[No Abstract] [Full Text] [Related]
25. Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
Ewins K; Malone A; Phelan E; Webb D; McHugh JC; Smith O
Br J Haematol; 2017 Oct; 179(2):294-297. PubMed ID: 28961308
[TBL] [Abstract][Full Text] [Related]
26. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
[TBL] [Abstract][Full Text] [Related]
27. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
28. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
[TBL] [Abstract][Full Text] [Related]
29. Acute methotrexate neurotoxicity revealed by a cerebellar syndrome.
Zahra K; Bouneb R; Mahjoub M; Zaghouani H; Zaier M; Ben Youssef Y; Khelif A
Rev Neurol (Paris); 2016 Dec; 172(12):791-793. PubMed ID: 27773447
[No Abstract] [Full Text] [Related]
30. Guillain-Barré syndrome mimicking acute methotrexate-associated encephalopathy in an adolescent patient with lymphoblastic lymphoma.
Terui K; Takahashi Y; Sasaki S; Kudo K; Kamio T; Ito E
J Pediatr Hematol Oncol; 2010 Nov; 32(8):615-6. PubMed ID: 20463610
[TBL] [Abstract][Full Text] [Related]
31. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
Kuhlen M; Bleckmann K; Möricke A; Schrappe M; Vieth S; Escherich G; Bronsema A; Vonalt A; Queudeville M; Zwaan CM; Ebinger M; Debatin KM; Klingebiel T; Koscielniak E; Rossig C; Burkhardt B; Kolb R; Eckert C; Borkhardt A; von Stackelberg A; Chen-Santel C
Br J Haematol; 2017 Oct; 179(2):272-283. PubMed ID: 28771662
[TBL] [Abstract][Full Text] [Related]
32. Clofarabine in pediatric acute leukemia: current findings and issues.
Hijiya N; Barry E; Arceci RJ
Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543
[TBL] [Abstract][Full Text] [Related]
33. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival.
Forcade E; Leguay T; Vey N; Baruchel A; Delaunay J; Robin M; Socié G; Dombret H; Peffault de Latour R; Raffoux E
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1124-6. PubMed ID: 23648236
[TBL] [Abstract][Full Text] [Related]
34. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
Karthik U; Motwani J
J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
[TBL] [Abstract][Full Text] [Related]
35. Reduced-dose carboxypeptidase-G2 successfully lowers elevated methotrexate levels in an adult with acute methotrexate-induced renal failure.
Trifilio S; Ma S; Petrich A
Clin Adv Hematol Oncol; 2013 May; 11(5):322-3. PubMed ID: 23880719
[No Abstract] [Full Text] [Related]
36. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia.
Pandey RK; DiPippo A; Kadia T; Pemmaraju N; Workeneh BT; Jabbour E; Ravandi F; Jain N
Leuk Lymphoma; 2020 Nov; 61(11):2775-2777. PubMed ID: 32654562
[No Abstract] [Full Text] [Related]
37. [Acute lymphoblastic leukemia in childhood. A 10-year experience with the DFCI 81-01 protocol].
de Lacerda AF; Chagas M; Neto A; Vieira E; Ribeiro MJ; Pereira F; Ambrósio A; Sousinha M
Acta Med Port; 1999; 12(7-11):287-92. PubMed ID: 10707467
[TBL] [Abstract][Full Text] [Related]
38. Acute methotrexate toxicity presenting with bullous lesions: an unusual presentation.
Sanke S; Yadav P; Chander R; Chandra J
Eur J Clin Pharmacol; 2017 Apr; 73(4):515-516. PubMed ID: 27975132
[No Abstract] [Full Text] [Related]
39. [Studies of childhood non-Hodgkin's lymphoma--treatment results with the CCLSG NHL 960 protocol. Children's Cancer and Leukemia Study Group (CCLSG)].
Tsurusawa M; Katano N; Hirota T; Ito M; Yanase T; Asami K; Koizumi S; Nakayama M; Miyawaki T; Suzumiya J; Nishikawa K; Mugisima H; Horikoshi Y; Hatae Y; Iwai A; Anami K; Kikuchi M; Osima K; Kaneko Y; Kataoka S; Tanaka A; Chin M; Taga T; Watanabe A; Fujimoto T
Rinsho Ketsueki; 1998 Nov; 39(11):1092-8. PubMed ID: 9866420
[TBL] [Abstract][Full Text] [Related]
40. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
Prescrire Int; 2009 Feb; 18(99):3-5. PubMed ID: 19382393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
